CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.
Power3 Medical Products, a company specializing in disease detection through the analysis of proteins, has filed for three patents on its blood test for the early detection of breast cancer.
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.
Center have created a test that could help doctors identify which breast cancer patients need aggressive therapy. The study, published in the online version of Clinical Cancer Research, could prevent many women from undergoing unnecessary chemotherapy or radiation treatment.
Copyright © 2025 | WordPress Theme by MH Themes